JSKN003 Versus Treatment Of Physician ' S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Conditions: Breast Cancer Interventions: Drug: JSKN003; Drug: Capecitabine tablets; Drug: Gemcitabine hydrochloride for injection; Drug: Vinorelbine tartrate injection; Drug: Paclitaxel for injection (albumin-bound type); Drug: Docetaxel injection; Drug: Eribulin mesylate injection Sponsors: Jiangsu Alphamab Biopharmaceuticals Co., Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Docetaxel | HER2 | Research | Taxotere | Xeloda